Heat Biologics (NASDAQ: HTBX) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Heat Biologics to related companies based on the strength of its institutional ownership, risk, analyst recommendations, dividends, valuation, profitability and earnings.
Valuation and Earnings
This table compares Heat Biologics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Heat Biologics||$777,132.00||-$11.53 million||-1.47|
|Heat Biologics Competitors||$464.94 million||$167.77 million||-6.72|
Heat Biologics’ rivals have higher revenue and earnings than Heat Biologics. Heat Biologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Heat Biologics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Heat Biologics Competitors||-4,766.77%||-354.87%||-43.42%|
Insider and Institutional Ownership
8.7% of Heat Biologics shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.7% of Heat Biologics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Heat Biologics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Heat Biologics’ rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.
This is a breakdown of recent recommendations for Heat Biologics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Heat Biologics Competitors||1380||4471||12311||312||2.63|
Heat Biologics currently has a consensus target price of $2.13, indicating a potential upside of 251.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.42%. Given Heat Biologics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Heat Biologics is more favorable than its rivals.
Heat Biologics rivals beat Heat Biologics on 7 of the 12 factors compared.
Heat Biologics Company Profile
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.